2023 World Conference on Lung Cancer (Posters)-P2.10. Brain Metastases in Patients with Fusion-Positive Lung Cancers

Pdf Summary

In a presentation titled "Brain Metastases in Patients with Fusion-Positive Lung Cancers" at the WCLC 2023 conference, researchers from Memorial Sloan Kettering Cancer Center in New York reported on the incidence of brain metastases (BrM) in patients with fusion-positive lung cancers and its impact on patient outcomes. The study included 9480 patients with non-small cell lung cancers, of which 438 patients (4.6%) had fusion-positive lung cancers. The incidence of BrM in fusion-positive lung cancers was found to be 41%. Among these cases, 60% had de novo presentation of brain metastases, while 40% developed them while on treatment.<br /><br />The researchers also assessed the overall survival (OS) of patients with and without brain metastases. The median time to development of brain metastases was found to be 34 months for ALK fusion-positive lung cancers, 30 months for ROS1, 24 months for RET, and 39 months for other fusions (BRAF, EGFR, ERBB2, FGFR1, MET, NRG1, NTRK). The median OS of patients without brain metastases was longer compared to those with brain metastases for RET fusion-positive lung cancers (47 vs 29 months) but did not show a significant difference for ALK and other fusions.<br /><br />The study highlights the high risk of developing brain metastases in patients with fusion-positive lung cancers and emphasizes the need for regular surveillance with brain imaging. The researchers also emphasize the importance of developing treatment strategies and targeted therapy agents with activity in the central nervous system for these patients. Overall, the findings shed light on the incidence and impact of brain metastases in fusion-positive lung cancers, providing important insights for future clinical management.

Asset Subtitle

Jane Sui

Meta Tag

Speaker Jane Sui

Topic Metastatic NSCLC: Targeted Therapy - FUSIONS

Keywords

Brain Metastases

Fusion-Positive Lung Cancers

Incidence

Patient Outcomes

Non-Small Cell Lung Cancers

De Novo Presentation

Treatment

Overall Survival

ALK Fusion-Positive Lung Cancers

ROS1 Fusion-Positive Lung Cancers